Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication

 
• By Jessica Merrill
Blue targets and three arrows reaching the center of the first one
Libtayo joins a competitive field with a new lung cancer indication • Source: Shutterstock (Shutterstock)

More from Immuno-oncology

More from Anticancer